The US pharmaceutical giant had an Israeli representative office for several many years before closing it.
Sources inform ''Globes'' that US pharmaceutical giant Bristol-Myers Squibb Co. (NYSE:BMY) is negotiating an Israel marketing and distribution agreement with Biotis Ltd..
Biotis is the Israeli representative of a number of international pharmaceutical companies, including Amdipharm plc, Methapharm Inc., Bavarian Nordic A/S (XETRA:BV3; KPX:BAVA). Bristol-Myers Squibb's top drugs include Baraclude for the treatment of hepatitis, Orencia for the treatment of rheumatoid arthritis, Reyataz for the treatment HIV, and Sprycell for the treatment of leukemia. These drugs are only available in Israel by private imports.
Biotis is a subsidiary of Shizim Ltd., a life sciences holding company. Shizim CEO Yossi Bornstein confirmed that negotiations were underway, but declined to elaborate.
Bristol-Myers Squibb had an Israeli representative office for several many years before closing it.
Published by Globes [online], Israel business news - www.globes-online.com - on December 25, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007